Symptomatic reflux disease: the present, the past and the future

The worldwide incidence of GORD and its complications is increasing along with the exponentially increasing problem of obesity. Of particular concern is the relationship between central adiposity and GORD complications, including oesophageal adenocarcinoma. Driven by progressive insight into the epi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Gut 2014-07, Vol.63 (7), p.1185-1193
Hauptverfasser: Boeckxstaens, Guy, El-Serag, Hashem B, Smout, André J P M, Kahrilas, Peter J
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1193
container_issue 7
container_start_page 1185
container_title Gut
container_volume 63
creator Boeckxstaens, Guy
El-Serag, Hashem B
Smout, André J P M
Kahrilas, Peter J
description The worldwide incidence of GORD and its complications is increasing along with the exponentially increasing problem of obesity. Of particular concern is the relationship between central adiposity and GORD complications, including oesophageal adenocarcinoma. Driven by progressive insight into the epidemiology and pathophysiology of GORD, the earlier belief that increased gastroesophageal reflux mainly results from one dominant mechanism has been replaced by acceptance that GORD is multifactorial. Instigating factors, such as obesity, age, genetics, pregnancy and trauma may all contribute to mechanical impairment of the oesophagogastric junction resulting in pathological reflux and accompanying syndromes. Progression of the disease by exacerbating and perpetuating factors such as obesity, neuromuscular dysfunction and oesophageal fibrosis ultimately lead to development of an overt hiatal hernia. The latter is now accepted as a central player, impacting on most mechanisms underlying gastroesophageal reflux (low sphincter pressure, transient lower oesophageal sphincter relaxation, oesophageal clearance and acid pocket position), explaining its association with more severe disease and mucosal damage. Since the introduction of proton pump inhibitors (PPI), clinical management of GORD has markedly changed, shifting the therapeutic challenge from mucosal healing to reduction of PPI-resistant symptoms. In parallel, it became clear that reflux symptoms may result from weakly acidic or non-acid reflux, insight that has triggered the search for new compounds or minimally invasive procedures to reduce all types of reflux. In summary, our view on GORD has evolved enormously compared to that of the past, and without doubt will impact on how to deal with GORD in the future.
doi_str_mv 10.1136/gutjnl-2013-306393
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4078752</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1534468604</sourcerecordid><originalsourceid>FETCH-LOGICAL-b567t-9843841df67c0441445167d905ce0f742f50fc86f5c5e741af2cbc1101d365b43</originalsourceid><addsrcrecordid>eNqNkUuP0zAUhS0EYkrhD7BAkdiwmMC98TMsEKOKl1SJBbC2HMfupMqj2M6I-ffjkqECVl1ZV_7u0bnnEPIc4TUiFW92c9qPfVkB0pKCoDV9QFbIhCpppdRDsgJAWXLJ6gvyJMY9AChV42NyUTEBsqZiRd5_ux0OaRpM6mwRnO_nX0XbRWeie1uka1ccgotuTJfLYGIqzNj-Hvyc5uCekkfe9NE9u3_X5MfHD983n8vt109fNlfbsuFCprJWjCqGrRfSAmPIGEch2xq4deAlqzwHb5Xw3HInGRpf2cYiArZU8IbRNXm36B7mZnCtzZ6C6fUhdIMJt3oynf73Z-yu9W660QykkrzKAq_uBcL0c3Yx6aGL1vW9Gd00R42SUyYl0jPQTOaYBRxtvfwP3U9zGHMSWVDWjNeCHQWrhbJhijHHfPKNoI9d6qVLfexSL13mpRd_X3xa-VNeBsoFaIb9OYJ3R5io4A</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1779459642</pqid></control><display><type>article</type><title>Symptomatic reflux disease: the present, the past and the future</title><source>MEDLINE</source><source>BMJ Journals - NESLi2</source><source>PubMed Central</source><creator>Boeckxstaens, Guy ; El-Serag, Hashem B ; Smout, André J P M ; Kahrilas, Peter J</creator><creatorcontrib>Boeckxstaens, Guy ; El-Serag, Hashem B ; Smout, André J P M ; Kahrilas, Peter J</creatorcontrib><description>The worldwide incidence of GORD and its complications is increasing along with the exponentially increasing problem of obesity. Of particular concern is the relationship between central adiposity and GORD complications, including oesophageal adenocarcinoma. Driven by progressive insight into the epidemiology and pathophysiology of GORD, the earlier belief that increased gastroesophageal reflux mainly results from one dominant mechanism has been replaced by acceptance that GORD is multifactorial. Instigating factors, such as obesity, age, genetics, pregnancy and trauma may all contribute to mechanical impairment of the oesophagogastric junction resulting in pathological reflux and accompanying syndromes. Progression of the disease by exacerbating and perpetuating factors such as obesity, neuromuscular dysfunction and oesophageal fibrosis ultimately lead to development of an overt hiatal hernia. The latter is now accepted as a central player, impacting on most mechanisms underlying gastroesophageal reflux (low sphincter pressure, transient lower oesophageal sphincter relaxation, oesophageal clearance and acid pocket position), explaining its association with more severe disease and mucosal damage. Since the introduction of proton pump inhibitors (PPI), clinical management of GORD has markedly changed, shifting the therapeutic challenge from mucosal healing to reduction of PPI-resistant symptoms. In parallel, it became clear that reflux symptoms may result from weakly acidic or non-acid reflux, insight that has triggered the search for new compounds or minimally invasive procedures to reduce all types of reflux. In summary, our view on GORD has evolved enormously compared to that of the past, and without doubt will impact on how to deal with GORD in the future.</description><identifier>ISSN: 0017-5749</identifier><identifier>EISSN: 1468-3288</identifier><identifier>DOI: 10.1136/gutjnl-2013-306393</identifier><identifier>PMID: 24607936</identifier><identifier>CODEN: GUTTAK</identifier><language>eng</language><publisher>England: BMJ Publishing Group LTD</publisher><subject>Acids ; Antacids - therapeutic use ; Combined Modality Therapy ; Disease Progression ; Endoscopy ; Epidemiology ; Gastroesophageal reflux ; Gastroesophageal Reflux - epidemiology ; Gastroesophageal Reflux - etiology ; Gastroesophageal Reflux - physiopathology ; Gastroesophageal Reflux - therapy ; Global Health ; Hernias ; Humans ; Laparoscopy ; Life Style ; Mortality ; Obesity ; Pathogenesis ; Proton Pump Inhibitors - therapeutic use ; Recent Advances in Clinical Practice ; Risk Factors ; Risk Reduction Behavior ; Studies ; Trends</subject><ispartof>Gut, 2014-07, Vol.63 (7), p.1185-1193</ispartof><rights>Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.</rights><rights>Copyright: 2014 Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b567t-9843841df67c0441445167d905ce0f742f50fc86f5c5e741af2cbc1101d365b43</citedby><cites>FETCH-LOGICAL-b567t-9843841df67c0441445167d905ce0f742f50fc86f5c5e741af2cbc1101d365b43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttp://gut.bmj.com/content/63/7/1185.full.pdf$$EPDF$$P50$$Gbmj$$Hfree_for_read</linktopdf><linktohtml>$$Uhttp://gut.bmj.com/content/63/7/1185.full$$EHTML$$P50$$Gbmj$$Hfree_for_read</linktohtml><link.rule.ids>114,115,230,314,723,776,780,881,3183,23550,27901,27902,53766,53768,77342,77373</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24607936$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Boeckxstaens, Guy</creatorcontrib><creatorcontrib>El-Serag, Hashem B</creatorcontrib><creatorcontrib>Smout, André J P M</creatorcontrib><creatorcontrib>Kahrilas, Peter J</creatorcontrib><title>Symptomatic reflux disease: the present, the past and the future</title><title>Gut</title><addtitle>Gut</addtitle><description>The worldwide incidence of GORD and its complications is increasing along with the exponentially increasing problem of obesity. Of particular concern is the relationship between central adiposity and GORD complications, including oesophageal adenocarcinoma. Driven by progressive insight into the epidemiology and pathophysiology of GORD, the earlier belief that increased gastroesophageal reflux mainly results from one dominant mechanism has been replaced by acceptance that GORD is multifactorial. Instigating factors, such as obesity, age, genetics, pregnancy and trauma may all contribute to mechanical impairment of the oesophagogastric junction resulting in pathological reflux and accompanying syndromes. Progression of the disease by exacerbating and perpetuating factors such as obesity, neuromuscular dysfunction and oesophageal fibrosis ultimately lead to development of an overt hiatal hernia. The latter is now accepted as a central player, impacting on most mechanisms underlying gastroesophageal reflux (low sphincter pressure, transient lower oesophageal sphincter relaxation, oesophageal clearance and acid pocket position), explaining its association with more severe disease and mucosal damage. Since the introduction of proton pump inhibitors (PPI), clinical management of GORD has markedly changed, shifting the therapeutic challenge from mucosal healing to reduction of PPI-resistant symptoms. In parallel, it became clear that reflux symptoms may result from weakly acidic or non-acid reflux, insight that has triggered the search for new compounds or minimally invasive procedures to reduce all types of reflux. In summary, our view on GORD has evolved enormously compared to that of the past, and without doubt will impact on how to deal with GORD in the future.</description><subject>Acids</subject><subject>Antacids - therapeutic use</subject><subject>Combined Modality Therapy</subject><subject>Disease Progression</subject><subject>Endoscopy</subject><subject>Epidemiology</subject><subject>Gastroesophageal reflux</subject><subject>Gastroesophageal Reflux - epidemiology</subject><subject>Gastroesophageal Reflux - etiology</subject><subject>Gastroesophageal Reflux - physiopathology</subject><subject>Gastroesophageal Reflux - therapy</subject><subject>Global Health</subject><subject>Hernias</subject><subject>Humans</subject><subject>Laparoscopy</subject><subject>Life Style</subject><subject>Mortality</subject><subject>Obesity</subject><subject>Pathogenesis</subject><subject>Proton Pump Inhibitors - therapeutic use</subject><subject>Recent Advances in Clinical Practice</subject><subject>Risk Factors</subject><subject>Risk Reduction Behavior</subject><subject>Studies</subject><subject>Trends</subject><issn>0017-5749</issn><issn>1468-3288</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>9YT</sourceid><sourceid>ACMMV</sourceid><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqNkUuP0zAUhS0EYkrhD7BAkdiwmMC98TMsEKOKl1SJBbC2HMfupMqj2M6I-ffjkqECVl1ZV_7u0bnnEPIc4TUiFW92c9qPfVkB0pKCoDV9QFbIhCpppdRDsgJAWXLJ6gvyJMY9AChV42NyUTEBsqZiRd5_ux0OaRpM6mwRnO_nX0XbRWeie1uka1ccgotuTJfLYGIqzNj-Hvyc5uCekkfe9NE9u3_X5MfHD983n8vt109fNlfbsuFCprJWjCqGrRfSAmPIGEch2xq4deAlqzwHb5Xw3HInGRpf2cYiArZU8IbRNXm36B7mZnCtzZ6C6fUhdIMJt3oynf73Z-yu9W660QykkrzKAq_uBcL0c3Yx6aGL1vW9Gd00R42SUyYl0jPQTOaYBRxtvfwP3U9zGHMSWVDWjNeCHQWrhbJhijHHfPKNoI9d6qVLfexSL13mpRd_X3xa-VNeBsoFaIb9OYJ3R5io4A</recordid><startdate>20140701</startdate><enddate>20140701</enddate><creator>Boeckxstaens, Guy</creator><creator>El-Serag, Hashem B</creator><creator>Smout, André J P M</creator><creator>Kahrilas, Peter J</creator><general>BMJ Publishing Group LTD</general><general>BMJ Publishing Group</general><scope>9YT</scope><scope>ACMMV</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>7T5</scope><scope>H94</scope><scope>5PM</scope></search><sort><creationdate>20140701</creationdate><title>Symptomatic reflux disease: the present, the past and the future</title><author>Boeckxstaens, Guy ; El-Serag, Hashem B ; Smout, André J P M ; Kahrilas, Peter J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b567t-9843841df67c0441445167d905ce0f742f50fc86f5c5e741af2cbc1101d365b43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Acids</topic><topic>Antacids - therapeutic use</topic><topic>Combined Modality Therapy</topic><topic>Disease Progression</topic><topic>Endoscopy</topic><topic>Epidemiology</topic><topic>Gastroesophageal reflux</topic><topic>Gastroesophageal Reflux - epidemiology</topic><topic>Gastroesophageal Reflux - etiology</topic><topic>Gastroesophageal Reflux - physiopathology</topic><topic>Gastroesophageal Reflux - therapy</topic><topic>Global Health</topic><topic>Hernias</topic><topic>Humans</topic><topic>Laparoscopy</topic><topic>Life Style</topic><topic>Mortality</topic><topic>Obesity</topic><topic>Pathogenesis</topic><topic>Proton Pump Inhibitors - therapeutic use</topic><topic>Recent Advances in Clinical Practice</topic><topic>Risk Factors</topic><topic>Risk Reduction Behavior</topic><topic>Studies</topic><topic>Trends</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Boeckxstaens, Guy</creatorcontrib><creatorcontrib>El-Serag, Hashem B</creatorcontrib><creatorcontrib>Smout, André J P M</creatorcontrib><creatorcontrib>Kahrilas, Peter J</creatorcontrib><collection>BMJ Open Access Journals</collection><collection>BMJ Journals:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Gut</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Boeckxstaens, Guy</au><au>El-Serag, Hashem B</au><au>Smout, André J P M</au><au>Kahrilas, Peter J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Symptomatic reflux disease: the present, the past and the future</atitle><jtitle>Gut</jtitle><addtitle>Gut</addtitle><date>2014-07-01</date><risdate>2014</risdate><volume>63</volume><issue>7</issue><spage>1185</spage><epage>1193</epage><pages>1185-1193</pages><issn>0017-5749</issn><eissn>1468-3288</eissn><coden>GUTTAK</coden><abstract>The worldwide incidence of GORD and its complications is increasing along with the exponentially increasing problem of obesity. Of particular concern is the relationship between central adiposity and GORD complications, including oesophageal adenocarcinoma. Driven by progressive insight into the epidemiology and pathophysiology of GORD, the earlier belief that increased gastroesophageal reflux mainly results from one dominant mechanism has been replaced by acceptance that GORD is multifactorial. Instigating factors, such as obesity, age, genetics, pregnancy and trauma may all contribute to mechanical impairment of the oesophagogastric junction resulting in pathological reflux and accompanying syndromes. Progression of the disease by exacerbating and perpetuating factors such as obesity, neuromuscular dysfunction and oesophageal fibrosis ultimately lead to development of an overt hiatal hernia. The latter is now accepted as a central player, impacting on most mechanisms underlying gastroesophageal reflux (low sphincter pressure, transient lower oesophageal sphincter relaxation, oesophageal clearance and acid pocket position), explaining its association with more severe disease and mucosal damage. Since the introduction of proton pump inhibitors (PPI), clinical management of GORD has markedly changed, shifting the therapeutic challenge from mucosal healing to reduction of PPI-resistant symptoms. In parallel, it became clear that reflux symptoms may result from weakly acidic or non-acid reflux, insight that has triggered the search for new compounds or minimally invasive procedures to reduce all types of reflux. In summary, our view on GORD has evolved enormously compared to that of the past, and without doubt will impact on how to deal with GORD in the future.</abstract><cop>England</cop><pub>BMJ Publishing Group LTD</pub><pmid>24607936</pmid><doi>10.1136/gutjnl-2013-306393</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0017-5749
ispartof Gut, 2014-07, Vol.63 (7), p.1185-1193
issn 0017-5749
1468-3288
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4078752
source MEDLINE; BMJ Journals - NESLi2; PubMed Central
subjects Acids
Antacids - therapeutic use
Combined Modality Therapy
Disease Progression
Endoscopy
Epidemiology
Gastroesophageal reflux
Gastroesophageal Reflux - epidemiology
Gastroesophageal Reflux - etiology
Gastroesophageal Reflux - physiopathology
Gastroesophageal Reflux - therapy
Global Health
Hernias
Humans
Laparoscopy
Life Style
Mortality
Obesity
Pathogenesis
Proton Pump Inhibitors - therapeutic use
Recent Advances in Clinical Practice
Risk Factors
Risk Reduction Behavior
Studies
Trends
title Symptomatic reflux disease: the present, the past and the future
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T21%3A54%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Symptomatic%20reflux%20disease:%20the%20present,%20the%20past%20and%20the%20future&rft.jtitle=Gut&rft.au=Boeckxstaens,%20Guy&rft.date=2014-07-01&rft.volume=63&rft.issue=7&rft.spage=1185&rft.epage=1193&rft.pages=1185-1193&rft.issn=0017-5749&rft.eissn=1468-3288&rft.coden=GUTTAK&rft_id=info:doi/10.1136/gutjnl-2013-306393&rft_dat=%3Cproquest_pubme%3E1534468604%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1779459642&rft_id=info:pmid/24607936&rfr_iscdi=true